Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
264
NCT03949530
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 16, 2019
Completion: Mar 29, 2020
NCT05514496
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
Start: Oct 5, 2022
Completion: Dec 1, 2025